May 17, 2023 7:00am EDT Sigyn Therapeutics Discloses “DEVICES FOR ENHANCING THE ACTIVITY OF THERAPEUTIC ANTIBODIES” Patent Submission and Related ImmunePrep™ Trademark Application
Apr 11, 2023 8:30am EDT Sigyn Therapeutics™ Announces Appointment of Annette Marleau, Ph.D. as Chief Scientific Officer
Oct 13, 2022 8:30am EDT Sigyn Therapeutics™ Discloses Trademark Applications to Register ChemoPrep™ and ChemoPure™ for Devices to Enhance Cancer Therapy
Oct 06, 2022 8:30am EDT Sigyn Therapeutics™ Announces Cancer-Related Patent Submission Entitled: “System and Methods to Enhance Chemotherapy Delivery and Reduce Toxicity”
Oct 04, 2022 9:00am EDT Sigyn Therapeutics™ Strengthens Board of Directors With the Appointments of Richa Nand, Jim Dorst and Christopher Wetzel
Sep 14, 2022 9:00am EDT Sigyn Therapeutics Announces First-In-Human Clinical Strategy to Address Inflammation and Endotoxemia in End-Stage Renal Disease Patients
